Biotech entity
Every one of those 1 sits in a single category, gene-therapy. Of the tracked stories, 1 of 1 also mention Bank of America, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention argenx SE, all published on September 9, 2026.
Last mentioned: 2d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, gene-therapy. Of the tracked stories, 1 of 1 also mention Bank of America, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention argenx SE, all published on September 9, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 5 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering argenx SE. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen rating actions
Wall Street Zen upgraded Tenaya from strong sell to sell and argenx from hold to buy.
Deutsche Bank downgrades argenx
Deutsche Bank cut argenx from buy to hold.
Truist raises argenx target
Truist Financial lifted its argenx target from $1,030.00 to $1,095.00 with a buy rating.
Tenaya Q2 miss
Tenaya reported EPS of -$0.20 versus -$0.07 expected and revenue of $1.11 million versus $10 million consensus.
Weiss Ratings upgrades Tenaya
Weiss Ratings moved Tenaya from sell (e+) to sell (d-), still within sell territory.
Baird raises argenx target
Robert W. Baird raised argenx target from $867.00 to $932.00 with a neutral rating.
argenx Q2 beat
argenx reported EPS of $7.32 versus $5.86 expected and revenue of $1.54 billion.
BofA lifts argenx target
Bank of America raised its price objective on argenx from $1,016.00 to $1,088.00 with a buy rating.
Wall Street Zen upgraded Tenaya from strong sell to sell, but the micro-cap gene therapy company still trades near a 52-week low after a sharp Q2 EPS and revenue miss. Biotech readers get a closer look at how clinical-stage execution failures are reflected in rating actions, while argenx's profitable rare disease business shows what commercial success looks like.
Source: tickerreport.com · dailypolitical.com
argenx SE is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
